



Marksans Pharma Ltd.

30th June, 2015

National Stock Exchange of India Limited
Listing Department
Exchange Plaza, C-1, Block -G
Bandra - Kurla Complex,
Bandra (E), Mumbai - 400051.

BSE Limited
Corporate Relation Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

Sub: News Release

Dear Sir,

Enclosed herewith kindly find a News Release dated 30th June, 2015 of the Company.

You are requested to note the above in your records.

Thanking You.

Yours faithfully,
For Marksans Pharma Limited

Harshavardhan Panigrahi
Company Secretary & Manager-Legal

Enclosed as above

CIN : L24110MH1992PLC066364

www.marksanspharma.com

Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara,
Andheri (W), Mumbai - 400 053 • Tel.: +91 22 4001 2000 • Fax : +91-22 4001 2011
E-mail: info@marksanspharma.com

News Release
30th June, 2015



Marksans Pharma Ltd.

This is to announce that Marksans Pharma Limited has, through its wholly owned subsidiary, Marksans Pharma Inc., acquired 100% of the outstanding shares of Time-Cap Laboratories, Inc., a New York corporation having its principal office at 7 Michael Avenue, Farmingdale, New York.

About Time-Cap Laboratories, Inc. ("Time-Cap")

Time-Cap was founded in 1979 and is a leading manufacturer and marketer of solid dose generic pharmaceuticals, including private label over-the-counter ("OTC") medications, generic prescription drugs ("Rx"), and nutritional supplements. Time-Cap manufactures over 50 unique products from its facility in Farmingdale, New York, including tablets, caplets, capsules and pellets. Time-Cap's average annual revenue over the last four years is in excess of USD 30 million per annum, and it achieved an average annual adjusted EBITDA of approximately USD 4 million. The company presently has no debt.

Key Highlights

- Time-Cap has a US FDA-approved manufacturing facility in Farmingdale, New York.
- It has an experienced research and development team which over the years has optimized its production processes and introduced a number of new products.
- Time-Cap has developed differentiating manufacturing expertise, resulting in a key competitive advantage in the market place for extended and delayed-release products, and coating services.
- The company has substantial growth opportunities with a robust new product line in the pipeline. Its capabilities with respect to extended-release products offer opportunities to pursue ANDAs for high margin products.
- Time-Cap has an expert management team comprised of industry pioneers with deep expertise, as well as a loyal and technically sophisticated employee base.

With its acquisition of Time-Cap, Marksans is strategically increasing its presence in the US market, which is the largest pharmaceutical market in the world. This transaction will be EPS accretive.

On this occasion, Mr. Mark Saldanha, Managing Director and CEO of Marksans Pharma Limited, offered the following remarks: "Time-Cap offers Marksans an ideal platform to expand its operation in the US. This strategic acquisition helps Marksans to expand its manufacturing capabilities along with product portfolio and penetration into the US"

About Marksans Pharma Limited

Marksans Pharma Limited (www.marksanspharma.com), headquartered at Mumbai, India, is a global pharmaceutical company actively engaged in R&D, manufacturing and marketing of generic pharmaceutical formulations in the global markets. The company's manufacturing facilities are approved by several leading regulatory agencies, such as the USFDA, UK MHRA, and Australian TGA. The company's robust product portfolio spans over major therapeutic segments, including CVS, CNS, Anti-diabetic, Pain Management, Gastroenterologicals and Anti-allergens. Marksans is marketing these products globally.

Forward-looking statement

This news release contains forward-looking statements that set out anticipated results based on the management's plans and assumption. Management can not guarantee that these forward looking statements will be realised, although the management believe they have been prudent in their assumptions. Achievement of results is subject to risks, uncertainties and even inaccurate assumptions.

CIN : L24110MH1992PLC066364



www.marksanspharma.com

Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai - 400 053 • Tel.: +91 22 4001 2000 • Fax : +91-22 4001 2011
E-mail: info@marksanspharma.com